Get the Stockscreener App
25.05
0.36%
-0.09
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $25.05, with a volume of 40.13M.
It is down -0.36% in the last 24 hours and down -3.36% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$25.14
Open:
$25.4
24h Volume:
40.13M
Relative Volume:
1.00
Market Cap:
$142.77B
Revenue:
$63.32B
Net Income/Loss:
$7.52B
P/E Ratio:
19.21
EPS:
1.3043
Net Cash Flow:
$9.48B
1W Performance:
+3.64%
1M Performance:
-3.36%
6M Performance:
-2.34%
1Y Performance:
+1.91%
1-Day Range:
$24.97
$25.65
1-Week Range:
$24.14
$25.65
52-Week Range:
$23.11
$28.75
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.05 | 143.28B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,179.11 | 1.04T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
253.04 | 601.73B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
254.49 | 449.45B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
127.50 | 315.22B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.76 | 291.42B | 54.66B | 13.58B | 16.05B | 7.0171 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Upgrade | Argus | Hold → Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Underperform |
| Feb-20-26 | Initiated | Barclays | Underweight |
| Feb-12-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-02-25 | Resumed | Citigroup | Neutral |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Pfizer Paid Out $14.6 Billion in Dividends Over the Last 18 Months. Can It Keep This Up Through the Patent Cliff? - The Motley Fool
How the Pfizer building scare could push developers to rethink vertical conversion plans - The Real Deal
Pfizer Stock Leads 3 AI Healthcare Names Worth Further Research - simplywall.st
Pfizer stock holds support as shares await fresh catalyst - ad-hoc-news.de
Can Pfizer (NYSE:PFE) Strengthen Its Pipeline Story? - Kalkine Media
Engineers blame lack of steel reinforcement on Pfizer HQ structural failure - The Real Deal
Dividend Roundup: JPMorgan Chase, Coca-Cola, Johnson & Johnson, Pfizer, and more - Seeking Alpha
McDonald's vs. PfizerThe Better Retirement Stock Isn't the One You'd Guess - AOL.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Elevance Health (ELV) and Pfizer (PFE) - The Globe and Mail
Pfizer stock holds steady as recent earnings and pipeline updates shape investor expectations - ad-hoc-news.de
Pfizer (PFE) Could Be 16% Undervalued On New FDA Approval In Bladder Cancer - simplywall.st
Form 4 Pfizer For: 16 July By Investing.com - Investing.com Canada
EXCLUSIVE: Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges - Reuters
Pfizer Inc. stock outperforms competitors on strong trading day - MarketWatch
Exclusive-Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges - WTAQ
Pfizer (PFE) Stock Looks Fairly Priced With Pipeline Risks In View - Yahoo Finance
Pfizer Stock Below 50-Day and 200-Day SMA: Buy the Dip or Exit Now? - Yahoo Finance
Arbutus Biopharma (ABUS) Files Lawsuits Against Pfizer and BioNT - GuruFocus
Arbutus Files More Patent Infringement Suits Against Pfizer, BioNTech -- Update - marketscreener.com
Arbutus Files More Patent Infringement Suits Against Pfizer, BioNTech - marketscreener.com
Pfizer, BioNTech face global patent suits from Arbutus, Roivant over COVID vaccine tech - Seeking Alpha
Arbutus and Genevant file patent lawsuits against Pfizer, BioNTech - Investing.com
Arbutus Biopharma Files International Patent Lawsuits Against Pfizer and BioNTech, Announces Moderna Settlement Payment and Plans for Capital Return - Quiver Quantitative
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders - The Manila Times
Pfizer captive Blue Whale Re holds A rating amid hard market participation - Insurance Business
Pfizer stock holds steady as pipeline and patent cycle shape long-term outlook - ad-hoc-news.de
Pfizer Abrysvo by Pfizer Inc.RSV vaccine targets seniors and pregnant women - Ad Hoc News
Pfizer (NYSE:PFE) Faces New Patent Claim After $96 Billion in COVID Vaccine Revenue - TechStock²
Is Earlier‑Stage PADCEV‑Keytruda Approval Reshaping The Investment Case For Pfizer (PFE)? - simplywall.st
Sanofi sues Pfizer, Moderna over COVID shot technology - Reuters
Pfizer building’s column scare tests Midtown East’s biggest conversion bet - The Real Deal
Celcuity shares fall as launch delay eclipses US approval for breast cancer drug - Reuters
Sanofi Sues Moderna, Pfizer for Vaccine-Tech Patent Royalties - Bloomberg Law News
Pfizer (PFE) Announces FDA Approval of PADCEV plus Keytruda in MIBC - Yahoo Finance
AM Best Affirms Credit Ratings of Blue Whale Re Ltd. - Business Wire
Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity? - 24/7 Wall St.
Prevnar 13 by Pfizer Inc.pneumococcal vaccine quietly powering a key franchise - Ad Hoc News
PFE Stock Quote Price and Forecast - CNN
Pfizer’s EPS Has Fallen 65% From Its Peak, Here’s Why That Might Be the Point - TIKR.com
Sanofi Says Pfizer, Moderna COVID Jabs Infringe MRNA Tech - Law360
Structural Failure at Pfizer Conversion Project Triggers Citywide Construction Review - Propmodo
Pfizer (PFE) Wins FDA Approval For First Platinum Free Bladder Cancer Regimen - Yahoo Finance
How Pfizer Won Fed. Circ. Patent Dispute By 1 Carbon Atom - Law360
Pfizer (PFE) Stock Looks Fully Priced After Its 21% Slump - simplywall.st
A week after the old NYC Pfizer building buckled, what’s new? - PIX11
Pfizer Vs. Amgen: Bet That Pfizer's Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen - 24/7 Wall St.
Pfizer Has the Highest-Yielding Dividend in the S&P 500. Should Investors Be Worried? - The Globe and Mail
Here's How Pfizer's Oncology Growth Story Looks Ahead of Q2 Results - Zacks Investment Research
Here's What to Expect From Pfizer's Next Earnings Report - Yahoo Finance
Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb - The Globe and Mail
Pfizer (NYSE:PFE) Holds 7% Yield as AI Selloff Hits, Options Traders Look for Protection - TechStock²
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.48%
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):